ClinicalTrials.gg
CompletedNCT00529568Updated Nov 5, 2013Results posted

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease

A Phase 3 interventional study of eltrombopag and placebo in Hepatitis C, Chronic, sponsored by GlaxoSmithKline. Completed at 227 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-05.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
759
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Hepatitis C, Chronic by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Hepatitis C, Chronic · GlaxoSmithKline.

Enrollment
3rd of 14
759 · median 62
Started
2007
with 2 others
Phase 3
4 of 14
none open now
Registered
8th of 14
by date

Among the 14 studies in Hepatitis C, Chronic by GlaxoSmithKline, this one is the 3rd largest by enrollment, is one of 3 that started in 2007, is one of 4 in phase 3, and was the 8th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 14 studies in Hepatitis C, Chronic by GlaxoSmithKline is open now. The open studies under Hepatitis C, Chronic, anywhere →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Hepatitis C, Chronic by GlaxoSmithKline as a file.
02

Study summary

The purpose of this study is to assess the ability of eltrombopag to maintain a platelet count sufficient to facilitate initiation of antiviral therapy, to minimise antiviral therapy dose reductions and to avoid permanent discontinuation of antiviral therapy. The clinical benefit of eltrombopag will be measured by the proportion of subjects who are able to achieve a Sustained Virological Response (SVR).

03

Conditions studied

  • Hepatitis C, Chronic

Keywords

  • hepatitis C
  • ribavirin
  • Hepatitis C-related thrombocytopenia
  • thrombopoietin
  • peginterferon alfa-2b
  • platelets
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male and female subjects, >18 years Evidence of chronic virus (HCV) infection Subjects who are appropriate candidates for peginterferon (pegIFN) and ribavirin antiviral therapy A count of \<75,000/mcL >11.0g/dL for men or >10.0g/dL for women (ANC) >750/mm3 and no history of infections associated with neutropenia >50mL/minute All fertile males and females must use two forms of effective between them during treatment and during the 24 weeks after treatment end Subject is able to understand, consent and comply with protocol requirements and instructions and is likely to complete the study as planned

Exclusion criteria

Exclusion criteria:

Non-responders to previous treatment with pegIFN and ribavirin who failed to achieve a sustained virologic response (SVR) for reasons other than thrombocytopenia, despite an optimal course (dose and duration) of combination therapy with pegIFN and ribavirin Decompensated liver disease, e.g. score >6 or history of ascites or hepatic encephalopathy or current evidence of ascites Known , intolerance or allergy to interferon (IFN), ribavirin, eltrombopag or any of their ingredients Serious cardiac, cerebrovascular, or pulmonary disease that would preclude treatment with pegIFN and ribavirin

Subjects with a history of any one of the following:

Suicide attempt or hospitalisation for depression in the past 5 years Any current severe or poorly controlled psychiatric disorder

The following subjects are eligible for study participation, but must be assessed and followed (if recommended) by a mental health professional:

  • Subjects who have had a severe or poorly controlled psychiatric disorder more than 6 months ago but less than 5 years ago
  • Seizure disorder that has not been well controlled History of bleeding from oesophageal or gastric varices Subjects with haemoglobinopathies, e.g. sickle cell anaemia, thalassemia major Any prior history of arterial or venous thrombosis AND two or more of the following risk factors: hereditary thrombophilic disorders (e.g. Factor V Leiden, ATIII deficiency, etc), hormone replacement therapy, systemic (containing estrogen), smoking, diabetes, hypercholesterolemia, medication for hypertension or cancer Pre-existing cardiac disease ( (NYHA) Grade III/IV), or arrhythmias known to involve the risk of thromboembolic events, or interval (QTc) >450 msec Evidence of hepatocellular carcinoma Laboratory evidence of infection with (HIV) or active Virus (HBV) infection Any disease condition associated with active bleeding or requiring anticoagulation with heparin or warfarin Therapy with any anti-neoplastic or immuno-modulatory treatment \<6 months prior to the first dose of eltrombopag.

Subjects who have had a diagnosed and/or treated within the past 5 years, except for subjects with localised basal or squamous cell carcinoma treated by local excision or subjects with malignancies who have been adequately treated and, in the opinion of the oncologist, have an excellent chance of cancer-free survival Pregnant or nursing women Males with a female partner who is pregnant History of alcohol/drug abuse or dependence within 6 months of the study start (unless participating in a controlled rehabilitation programme) Treatment with an drug or IFN within 30 days or 5 half-lives (whichever is longer) of the screening visit History of clumping that prevents reliable measurement of platelet counts History of major organ transplantation with an existing functional graft Thyroid dysfunction not adequately controlled Subjects planning to have cataract surgery Evidence of portal vein thrombosis on abdominal imaging within 3 months of the baseline visit

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
759 participants (actual)

Study arms

  • Experimental
    eltrombopag

    active treatment arm

    Drug: eltrombopag

  • Placebo comparator
    placebo

    placebo control arm

    Drug: placebo

Interventions

  • double-blind active treatment daily oral administation at dose of 25, 50, 75, or 100 mg

  • Drugplacebo

    double-blind matched placebo control daily oral administration

06

What researchers measure

Primary outcomes

  1. Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase

    Participants with SVR are defined as those with non-detectable Hepatitis C Virus (HCV) ribonucleic acid (RNA) at the end of treatment and all subsequent planned visits up to 24 weeks post-completion of the treatment period of the DB Phase.

    Time frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)

Secondary outcomes

  1. Number of Participants Whose Platelet Count Increased From a Baseline Count of <75 Gi/L to a Count Greater Than or Equal to (>=) 100 Giga (10^9) Cells Per Liter (Gi/L) During the Open-label (OL) Pre-Antiviral Treatment Phase

    Participants were assessed for a shift from a baseline platelet count of \<75 Gi/L to a count \>=100 Gi/L during the OL Phase (up to 9 weeks). Local laboratories were used for platelet function tests. Platelet counts were measured by blood draw.

    Time frame: From Baseline up to Week 9 in the OL Phase

  2. Number of Participants Receiving the Indicated Doses of Eltrombopag in the OL Phase Who Initiated Antiviral Therapy (Peginterferon Alfa-2a and Ribavirin) in the DB Phase

    In the OL Phase, participants initially received the lowest dose of eltrombopag (25 mg QD) for 2 weeks. If after this time the platelet count was \<100 Gi/L, participants underwent sequential dose escalation to the next highest dose (50 mg QD for up to 2 weeks), with further dose escalations to 75 mg QD (up to 2 weeks) and 100 mg QD (up to a maximum of 3 weeks) if platelet counts remained \<100 Gi/L. Participants who achieved platelet counts \>=100 Gi/L when receiving any of the eltrombopag doses in the OL Phase initiated antiviral therapy in the DB Phase.

    Time frame: From Baseline up to Week 9 in the OL Phase

  3. Median Platelet Count at the Indicated Time Points During the OL Phase

    Blood taken from peripheral blood vessels was used for the measurement of platelet counts. The Last On Treatment assessment refers to the actual last treatment assessment, not necessarily to the End of Treatment assessment entered by the Investigator.

    Time frame: OL Phase: Baseline; Day 1; Weeks 1, 2, 3, 4, 5, 6, 7, 8, and 9; Antiviral Baseline (up to Week 10); End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 62); 12-week FU (up to Week 70); and 24-week FU (up to Week 82)

  4. Median Platelet Count at the Indicated Time Points During the DB Phase

    Blood taken from peripheral blood vessels was used for the measurement of platelet counts. The Last On Treatment assessment refers to the actual last treatment assessment, not necessarily to the End of Treatment assessment entered by the Investigator.

    Time frame: DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)

  5. Number of Participants in the Indicated Categories for Minimum Platelet Count With Antiviral Therapy

    The minimum platelet count with antiviral therapy was categorized as follows: \<25 Gi/L; \>=25 to \<50 Gi/L; \>=50 to \<90 Gi/L; \>=90 to \<150 Gi/L; \>=150 Gi/L to \<200 Gi/L; \>=200 Gi/L to \<400 Gi/L; and \>=400 Gi/L.

    Time frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)

  6. Number of Participants With Rapid Virological Response (RVR) and Extended RVR (eRVR) During the DB Phase

    RVR is defined as the absence of detectable HCV RNA after 4 weeks of antiviral treatment. eRVR is defined as the absence of detectable HCV RNA after 4 weeks of antiviral treatment that persisted through Week 12.

    Time frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)

  7. Number of Participants With Early Virological Response (EVR) and Complete EVR (cEVR) During the DB Phase

    EVR is defined as a clinically significant reduction from Baseline in HCV RNA (\>=2 log10 drop or undetectable) after 12 weeks of antiviral treatment. cEVR is defined as undetectable HCV RNA after 12 weeks of antiviral treatment.

    Time frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)

  8. Number of Participants With End of Treatment Response (ETR) and Sustained Virological Response at Week 12 of Follow-up (SVR12) During the DB Phase

    ETR is defined as the absence of detectable HCV RNA at the end of antiviral treatment. SVR12 is defined as the absence of detectable HCV RNA at the end of antiviral treatment and the 12-week follow-up assessment.

    Time frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)

  9. Number of Participants in the Indicated Categories for Antiviral Therapy Dose Reductions in the DB Phase

    Participants were assigned a score equal to the number of times their dose of antiviral therapy (peginterferon or ribavirin) was reduced (0=no dose reductions \[DRs\]; 1=one DR; 2=two DRs; 3=three DRs; \>3=more than three DRs). When possible, every effort was made to maintain the recommended dose of antiviral therapy for the treatment duration in the DB Phase. However, when dose modification of antiviral therapy was required due to safety concerns, it was performed by the Investigator as per the region-specific product labels of peginterferon and ribavirin.

    Time frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)

  10. Time to First Dose Reduction of Peginterferon Alfa-2a and Ribavirin Therapy in the DB Phase

    Time to first dose reduction was calculated as the time period from the first dose to the first dose reduction.

    Time frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)

  11. Number of Participants With the Indicated Levels of Peginterferon Dose Reductions in the DB Phase

    The assigned dose in the DB Phase of peginterferon alfa-2a was 180 micrograms (µg). For peginterferon dose modification, downward adjustments in one-level increments were considered. The lowest dose of peginterferon alfa-2a that was allowed to be administered was 45 µg. When dose adjustment was required for moderate to severe adverse reactions (clinical and/or laboratory), an initial dose reduction to 135 µg was generally adequate. In some cases, a dose reduction to 90 µg or 45 µg was necessary. Dose increases toward the original dose were considered when the adverse reaction was resolved.

    Time frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)

  12. Number of Participants Who Prematurely Discontinued Antiviral Therapy in the DB Phase

    The following participants were considered to have discontinued antiviral therapy: participants who were lost to follow-up; participants who withdrew for any reason; participants who died; participants who otherwise did not complete their planned course of antiviral therapy for any reason. The planned duration of antiviral therapy was 48 weeks for participants with Non-Genotype 2/3 and 24 or 48 weeks for participants with Genotype 2/3.

    Time frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)

  13. Number of Participants Categorized as Responders (R) and Non-responders (NR) for SVR and RVR to Antiviral Therapy in the Indicated Variants of Interleukin 28B (IL28B) (or Interferon, Lambda 3)

    There are two genetic variants (rs12979860 and rs8099917) mapping near IL28B associated with both interferon-induced SVR and spontaneous HCV clearance. IL28B genotype distribution by response to antiviral therapy (SVR/RVR responders: those who achieved SVR/RVR; SVR/RVR non-responders: those who did not achieve SVR/RVR) was assessed. The effect of genotype was tested by comparing participants that carried 2 copies of the IL28B favorable response allele versus the others (recessive model). Genotypes at rs12979860 were coded as: CC=1, CT or TT=0; rs8099917 was coded as TT=1, GT or GG=0.

    Time frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)

  14. Number of Participants With the Indicated Shift From Baseline (BL) in Severity Grades for Clinical Chemistry Parameters (Calcium, Glucose [Glu.], Potassium [Pot.], and Sodium [Sod.]), Per Division of Acquired Immunodeficiency Syndrome (DAIDS)

    Blood samples for the assessment of clinical chemistry parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL during the DB Phase are reported, per severity grades by DAIDS, for levels of calcium (low=hypocalcemia; high=hypercalcemia), glu. (low=hypoglycemia; high=hyperglycemia), pot. (low=hypokalemia; high=hyperkalemia), and sod. (low=hyponatremia; high=hypernatremia). Per the DAIDS toxicity table, the grade ranges for each parameter are as follows: Grade (G) 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.

    Time frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)

  15. Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters (Hemoglobin, Lymphocytes [Lym.], Total Neutrophils [Tot Neu.], and White Blood Cells [WBC]), Per DAIDS

    Blood samples for the assessment of hematology parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL during the DB Phase are reported, per severity grades by DAIDS, for levels of hemoglobin (low=anemia), lymphocytes (low=lymphocytopenia), total neutrophils (low=neutropenia), and white blood cells (low=leukocytopenia). Per the DAIDS toxicity table, grade ranges for each parameter are as follows: Grade (G) 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.

    Time frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)

  16. Number of Participants in the Indicated Categories for Cataract Event During the DB Phase, Per Clinical Events Committee (CEC) Adjudication

    Ophthalmic (pertaining to eye) assessments were performed during the study. A cataract event is defined as an event ascertained to be a cataract (opacity or cloudiness of the lens of the eye, causing impairment of vision) by at least one of the CEC members (comprised of expert ophthalmologists who provided objective medical review of the blinded ophthalmic data). Per the CEC, cataract events were categorized as: (1) Cataract Progression (CP; progression of cataracts present at BL); and (2) Incident Cataract (IC; development of new cataracts). One eye=unilateral; both eyes=bilateral.

    Time frame: From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)

  17. Number of Participants Assessed as Normal and Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at the Indicated Time Points During the DB Phase

    Duplicate 12-lead ECGs were required at Screening/BL, Antiviral BL, and at 12 weekly intervals during the study. The number of participants with an ECG status of normal, abnormal, CS, or NCS, as determined by the Investigator, was reported. Normal, all ECG parameters within accepted normal ranges. Abnormal, ECG finding(s) outside of normal ranges. CS, ECG with a CS abnormality that meets exclusion criteria. NCS, ECG with an abnormality not CS or meeting exclusion criteria, per Investigator, based on reasonable standards of clinical judgment.

    Time frame: DB Phase: Antiviral BL (up to Week 10); End of Treatment (up to Week 52); and 24-week FU (up to Week 72)

  18. Number of Participants With CS and NCS Change From Baseline for 12-lead ECG at the Indicated Time Points During the DB Phase

    Duplicate 12-lead ECGs were required at Screening/BL, Antiviral BL, and at 12 weekly intervals during the study. The number of participants with a CS and a NCS change from baseline in ECG status, as determined by the Investigator, was reported. CS, ECG with a CS abnormality that meets exclusion criteria. NCS, ECG with an abnormality not CS or meeting exclusion criteria, per Investigator, based on reasonable standards of clinical judgment. "Not applicable" indicates that information was not provided by the investigator on whether the change from baseline ECG was CS or NCS.

    Time frame: End of Treatment (up to Week 52); and 24-week FU (up to Week 72)

  19. Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points During the DB Phase

    Participant's blood pressure was measured at the indicated time points during the study. Systolic blood pressure is a measure of blood pressure while the heart is beating. Diastolic blood pressure is a measure of blood pressure while the heart is relaxed. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.

    Time frame: DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)

  20. Mean Change From Baseline in Heart Rate at the Indicated Time Points During the DB Phase

    Heart rate was measured in participants at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.

    Time frame: DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)

  21. Mean Change From Baseline in Weight at the Indicated Time Points During the DB Phase

    The weight of participants was recorded at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.

    Time frame: DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)

  22. Mean Change From Baseline in Body Mass Index (BMI) at the Indicated Time Points During the DB Phase

    The BMI for participants was calculated at the indicated time points as body weight in kilograms divided by height in meters squared. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.

    Time frame: DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)

07

Results

Posted May 17, 2012

Participant flow

Open-label Pre-Antiviral Treatment Phase
Participant flow — Open-label Pre-Antiviral Treatment Phase
MilestoneEltrombopag: Open-label PhasePlacebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB Phase
Started80500
Completed75900
Not completed4600
Withdrew: Adverse event500
Withdrew: Lost to follow-up1200
Withdrew: Protocol violation500
Withdrew: Physician decision800
Withdrew: Insufficient platelet response1300
Withdrew: Withdrawal by subject300
Double-bilnd Antiviral Treatment Phase
Participant flow — Double-bilnd Antiviral Treatment Phase
MilestoneEltrombopag: Open-label PhasePlacebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB Phase
Started0253506
Completed0205404
Not completed048102
Withdrew: Adverse event01027
Withdrew: Protocol violation010
Withdrew: Lost to follow-up01548
Withdrew: Physician decision058
Withdrew: Withdrawal by subject01719

Outcome measures

PrimaryNumber of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase

Participants with SVR are defined as those with non-detectable Hepatitis C Virus (HCV) ribonucleic acid (RNA) at the end of treatment and all subsequent planned visits up to 24 weeks post-completion of the treatment period of the DB Phase.

Time frame:
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Reported as:
Number · participants
Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase
participantsPlacebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB Phase
Number of Participants With Sustained Virologic Response (SVR) in the Double-blind (DB) Antiviral Treatment Phase3297
Statistical analysis
  • Placebo+Antiviral Therapy: DB Phase vs Eltrombopag+Antiviral Therapy: DB Phase · Cochran-Mantel-Haenszel · p = 0.0202 (Stratified Cochran-Mantel-Haenszel (CMH) chi-square test adjusted for the randomization strata) · Percentage difference in svr: 6.0 · 95% CI 1.2 to 10.9The estimated value reflects the percentage of participants with SVR in the eltrombopag group minus the percentage of participants with SVR in the placebo group. Adjusted for the actual strata: HCV genotype, baseline platelet count, and HCV RNA.
SecondaryNumber of Participants Whose Platelet Count Increased From a Baseline Count of <75 Gi/L to a Count Greater Than or Equal to (>=) 100 Giga (10^9) Cells Per Liter (Gi/L) During the Open-label (OL) Pre-Antiviral Treatment Phase

Participants were assessed for a shift from a baseline platelet count of \<75 Gi/L to a count \>=100 Gi/L during the OL Phase (up to 9 weeks). Local laboratories were used for platelet function tests. Platelet counts were measured by blood draw.

Time frame:
From Baseline up to Week 9 in the OL Phase
Reported as:
Number · participants
Number of Participants Whose Platelet Count Increased From a Baseline Count of <75 Gi/L to a Count Greater Than or Equal to (>=) 100 Giga (10^9) Cells Per Liter (Gi/L) During the Open-label (OL) Pre-Antiviral Treatment Phase
participantsEltrombopag: OL Phase
Number of Participants Whose Platelet Count Increased From a Baseline Count of <75 Gi/L to a Count Greater Than or Equal to (>=) 100 Giga (10^9) Cells Per Liter (Gi/L) During the Open-label (OL) Pre-Antiviral Treatment Phase773
SecondaryNumber of Participants Receiving the Indicated Doses of Eltrombopag in the OL Phase Who Initiated Antiviral Therapy (Peginterferon Alfa-2a and Ribavirin) in the DB Phase

In the OL Phase, participants initially received the lowest dose of eltrombopag (25 mg QD) for 2 weeks. If after this time the platelet count was \<100 Gi/L, participants underwent sequential dose escalation to the next highest dose (50 mg QD for up to 2 weeks), with further dose escalations to 75 mg QD (up to 2 weeks) and 100 mg QD (up to a maximum of 3 weeks) if platelet counts remained \<100 Gi/L. Participants who achieved platelet counts \>=100 Gi/L when receiving any of the eltrombopag doses in the OL Phase initiated antiviral therapy in the DB Phase.

Time frame:
From Baseline up to Week 9 in the OL Phase
Reported as:
Number · participants
Number of Participants Receiving the Indicated Doses of Eltrombopag in the OL Phase Who Initiated Antiviral Therapy (Peginterferon Alfa-2a and Ribavirin) in the DB Phase
participantsEltrombopag: OL Phase
25 mg443
50 mg208
75 mg77
100 mg31
SecondaryMedian Platelet Count at the Indicated Time Points During the OL Phase

Blood taken from peripheral blood vessels was used for the measurement of platelet counts. The Last On Treatment assessment refers to the actual last treatment assessment, not necessarily to the End of Treatment assessment entered by the Investigator.

Time frame:
OL Phase: Baseline; Day 1; Weeks 1, 2, 3, 4, 5, 6, 7, 8, and 9; Antiviral Baseline (up to Week 10); End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 62); 12-week FU (up to Week 70); and 24-week FU (up to Week 82)
Reported as:
Median · Gi/L
Median Platelet Count at the Indicated Time Points During the OL Phase
Gi/LEltrombopag: OL Phase
Baseline, n=79759.0 (12 to 95)
Day 1, n=71458.0 (5 to 117)
Week 1, n=79177.0 (5 to 223)
Week 2, n=53093.0 (9 to 489)
Week 3, n=28889.0 (10 to 504)
Week 4, n=16190.0 (10 to 280)
Week 5, n=9892.0 (9 to 252)
Week 6, n=5586.0 (14 to 138)
Week 7, n=3578.0 (11 to 136)
Week 8, n=2487.5 (15 to 146)
Week 9, n=485.5 (66 to 107)
Antiviral Baseline, n=48131.5 (76 to 274)
End of Treatment/Withdrawal, n=2276.5 (13 to 257)
Last on Treatment, n=3987.0 (13 to 267)
Week 4 Follow-Up, n=2042.0 (11 to 156)
Week 12 Follow-Up, n=1543.0 (8 to 91)
Week 24 Follow-Up, n=1441.0 (13 to 87)
SecondaryMedian Platelet Count at the Indicated Time Points During the DB Phase

Blood taken from peripheral blood vessels was used for the measurement of platelet counts. The Last On Treatment assessment refers to the actual last treatment assessment, not necessarily to the End of Treatment assessment entered by the Investigator.

Time frame:
DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)
Reported as:
Median · Gi/L
Median Platelet Count at the Indicated Time Points During the DB Phase
Gi/LPlacebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB Phase
Baseline, n=238, 460140.0 (63 to 365)136.0 (43 to 400)
Week 1, n=247, 494120.0 (42 to 366)116.0 (46 to 466)
Week 2, n=244, 49289.5 (27 to 318)124.0 (38 to 553)
Week 4, n=228, 48751.0 (20 to 180)105 (19 to 389)
Week 6, n=206, 47349.5 (20 to 200)100.0 (22 to 417)
Week 8, n=192, 47350.0 (10 to 191)100.0 (19 to 486)
Week 12, n=176, 45149.7 (21 to 264)104.0 (10 to 444)
Week 16, n=145, 40548.0 (20 to 262)102.0 (13 to 365)
Week 20, n=134, 37850.0 (23 to 257)103.0 (21 to 373)
Week 24, n=99, 26349.0 (19 to 200)102.0 (18 to 448)
Week 28, n=74, 21252.5 (22 to 193)102.0 (20 to 355)
Week 32, n=67, 19949.0 (22 to 195)107.0 (14 to 295)
Week 36, n=63, 18550.0 (16 to 198)106.0 (29 to 268)
Week 40, n=58, 17453.7 (19 to 195)106.5 (10 to 351)
Week 44, n=59, 16853.0 (26 to 197)108.7 (26 to 330)
End of Treatment/Withdrawal, n=240, 46851.0 (10 to 275)106.5 (10 to 445)
Last on Treatment, n=253, 50550.0 (17 to 300)105.0 (10 to 330)
4 week follow up, n=221, 42463.0 (4 to 225)89.0 (12 to 333)
12 week follow up, n=209, 43057.0 (15 to 285)62.0 (8 to 280)
24 week follow up, n=201, 39557.0 (8 to 231)59.0 (4 to 297)
SecondaryNumber of Participants in the Indicated Categories for Minimum Platelet Count With Antiviral Therapy

The minimum platelet count with antiviral therapy was categorized as follows: \<25 Gi/L; \>=25 to \<50 Gi/L; \>=50 to \<90 Gi/L; \>=90 to \<150 Gi/L; \>=150 Gi/L to \<200 Gi/L; \>=200 Gi/L to \<400 Gi/L; and \>=400 Gi/L.

Time frame:
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Reported as:
Number · participants
Number of Participants in the Indicated Categories for Minimum Platelet Count With Antiviral Therapy
participantsPlacebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB Phase
<25 Gi/L3420
>=25 to <50 Gi/L15976
>=50 to <90 Gi/L49263
>=90 to <150 Gi/L10135
>=150 to <200 Gi/L08
>=200 to <400 Gi/L04
>=400 Gi/L00
Missing10
SecondaryNumber of Participants With Rapid Virological Response (RVR) and Extended RVR (eRVR) During the DB Phase

RVR is defined as the absence of detectable HCV RNA after 4 weeks of antiviral treatment. eRVR is defined as the absence of detectable HCV RNA after 4 weeks of antiviral treatment that persisted through Week 12.

Time frame:
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Reported as:
Number · participants
Number of Participants With Rapid Virological Response (RVR) and Extended RVR (eRVR) During the DB Phase
participantsPlacebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB Phase
RVR3478
eRVR2769
SecondaryNumber of Participants With Early Virological Response (EVR) and Complete EVR (cEVR) During the DB Phase

EVR is defined as a clinically significant reduction from Baseline in HCV RNA (\>=2 log10 drop or undetectable) after 12 weeks of antiviral treatment. cEVR is defined as undetectable HCV RNA after 12 weeks of antiviral treatment.

Time frame:
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Reported as:
Number · participants
Number of Participants With Early Virological Response (EVR) and Complete EVR (cEVR) During the DB Phase
participantsPlacebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB Phase
EVR103313
cEVR57174
SecondaryNumber of Participants With End of Treatment Response (ETR) and Sustained Virological Response at Week 12 of Follow-up (SVR12) During the DB Phase

ETR is defined as the absence of detectable HCV RNA at the end of antiviral treatment. SVR12 is defined as the absence of detectable HCV RNA at the end of antiviral treatment and the 12-week follow-up assessment.

Time frame:
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Reported as:
Number · participants
Number of Participants With End of Treatment Response (ETR) and Sustained Virological Response at Week 12 of Follow-up (SVR12) During the DB Phase
participantsPlacebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB Phase
ETR59190
SVR1229106
SecondaryNumber of Participants in the Indicated Categories for Antiviral Therapy Dose Reductions in the DB Phase

Participants were assigned a score equal to the number of times their dose of antiviral therapy (peginterferon or ribavirin) was reduced (0=no dose reductions \[DRs\]; 1=one DR; 2=two DRs; 3=three DRs; \>3=more than three DRs). When possible, every effort was made to maintain the recommended dose of antiviral therapy for the treatment duration in the DB Phase. However, when dose modification of antiviral therapy was required due to safety concerns, it was performed by the Investigator as per the region-specific product labels of peginterferon and ribavirin.

Time frame:
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Reported as:
Number · participants
Number of Participants in the Indicated Categories for Antiviral Therapy Dose Reductions in the DB Phase
participantsPlacebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB Phase
068231
176101
24075
33447
>33552
SecondaryTime to First Dose Reduction of Peginterferon Alfa-2a and Ribavirin Therapy in the DB Phase

Time to first dose reduction was calculated as the time period from the first dose to the first dose reduction.

Time frame:
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Reported as:
Mean · weeks
Time to First Dose Reduction of Peginterferon Alfa-2a and Ribavirin Therapy in the DB Phase
weeksPlacebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB Phase
Peginterferon alfa-2a dose reduction, n=171, 2086.58 ± 7.33610.64 ± 9.305
Ribavirin dose reduction, n=79, 18912.43 ± 9.68110.99 ± 8.984
SecondaryNumber of Participants With the Indicated Levels of Peginterferon Dose Reductions in the DB Phase

The assigned dose in the DB Phase of peginterferon alfa-2a was 180 micrograms (µg). For peginterferon dose modification, downward adjustments in one-level increments were considered. The lowest dose of peginterferon alfa-2a that was allowed to be administered was 45 µg. When dose adjustment was required for moderate to severe adverse reactions (clinical and/or laboratory), an initial dose reduction to 135 µg was generally adequate. In some cases, a dose reduction to 90 µg or 45 µg was necessary. Dose increases toward the original dose were considered when the adverse reaction was resolved.

Time frame:
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Reported as:
Number · participants
Number of Participants With the Indicated Levels of Peginterferon Dose Reductions in the DB Phase
participantsPlacebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB Phase
<=25%4489
>25% to <=34%3335
>34% to <=50%115112
>50%3330
SecondaryNumber of Participants Who Prematurely Discontinued Antiviral Therapy in the DB Phase

The following participants were considered to have discontinued antiviral therapy: participants who were lost to follow-up; participants who withdrew for any reason; participants who died; participants who otherwise did not complete their planned course of antiviral therapy for any reason. The planned duration of antiviral therapy was 48 weeks for participants with Non-Genotype 2/3 and 24 or 48 weeks for participants with Genotype 2/3.

Time frame:
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Reported as:
Number · participants
Number of Participants Who Prematurely Discontinued Antiviral Therapy in the DB Phase
participantsPlacebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB Phase
Number of Participants Who Prematurely Discontinued Antiviral Therapy in the DB Phase164242
SecondaryNumber of Participants Categorized as Responders (R) and Non-responders (NR) for SVR and RVR to Antiviral Therapy in the Indicated Variants of Interleukin 28B (IL28B) (or Interferon, Lambda 3)

There are two genetic variants (rs12979860 and rs8099917) mapping near IL28B associated with both interferon-induced SVR and spontaneous HCV clearance. IL28B genotype distribution by response to antiviral therapy (SVR/RVR responders: those who achieved SVR/RVR; SVR/RVR non-responders: those who did not achieve SVR/RVR) was assessed. The effect of genotype was tested by comparing participants that carried 2 copies of the IL28B favorable response allele versus the others (recessive model). Genotypes at rs12979860 were coded as: CC=1, CT or TT=0; rs8099917 was coded as TT=1, GT or GG=0.

Time frame:
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Reported as:
Number · participants
Number of Participants Categorized as Responders (R) and Non-responders (NR) for SVR and RVR to Antiviral Therapy in the Indicated Variants of Interleukin 28B (IL28B) (or Interferon, Lambda 3)
participantsPlacebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB Phase
SVR, rs12979860 (CC), R; n=12, 501028
SVR, rs12979860 (CC), NR; n=105, 2052458
SVR, rs12979860 (CT), R; n=12, 50218
SVR, rs12979860 (CT), NR; n=105, 20560111
SVR, rs12979860 (TT), R; n=12, 5004
SVR, rs12979860 (TT), NR; n=105, 2052136
SVR, rs8099917 (TT), R; n=12, 501136
SVR, rs8099917 (TT), NR; n=105, 2054889
SVR, rs8099917 (GT), R; n=12, 50113
SVR, rs8099917 (GT), NR; n=105, 2055199
SVR, rs8099917 (GG), R; n=12, 5001
SVR, rs8099917 (GG), NR; n=105, 205617
RVR, rs12979860 (CC), R; n=11, 33621
RVR, rs12979860 (CC), NR; n=106, 2222865
RVR, rs12979860 (CT), R; n=11, 33511
RVR, rs12979860 (CT), NR; n=106, 22257118
RVR, rs12979860 (TT), R; n=11, 3301
RVR, rs12979860 (TT), NR; n=106, 2222139
RVR, rs8099917 (TT), R, n=11, 33928
RVR, rs8099917 (TT), NR; n=106, 2225097
RVR, rs8099917 (GT), R; n=11, 3325
RVR, rs8099917 (GT), NR; n=106, 22250107
RVR, rs8099917 (GG), R; n=11, 3300
RVR, rs8099917 (GG), R; n=106, 222618
SecondaryNumber of Participants With the Indicated Shift From Baseline (BL) in Severity Grades for Clinical Chemistry Parameters (Calcium, Glucose [Glu.], Potassium [Pot.], and Sodium [Sod.]), Per Division of Acquired Immunodeficiency Syndrome (DAIDS)

Blood samples for the assessment of clinical chemistry parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL during the DB Phase are reported, per severity grades by DAIDS, for levels of calcium (low=hypocalcemia; high=hypercalcemia), glu. (low=hypoglycemia; high=hyperglycemia), pot. (low=hypokalemia; high=hyperkalemia), and sod. (low=hyponatremia; high=hypernatremia). Per the DAIDS toxicity table, the grade ranges for each parameter are as follows: Grade (G) 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.

Time frame:
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Reported as:
Number · participants
Number of Participants With the Indicated Shift From Baseline (BL) in Severity Grades for Clinical Chemistry Parameters (Calcium, Glucose [Glu.], Potassium [Pot.], and Sodium [Sod.]), Per Division of Acquired Immunodeficiency Syndrome (DAIDS)
participantsPlacebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB Phase
Calcium (hypocalcemia), Any Grade Increase184374
Calcium (hypocalcemia), Increase to G1140246
Calcium (hypocalcemia), Increase to G242122
Calcium (hypocalcemia), Increase to G324
Calcium (hypocalcemia), Increase to G402
Calcium (hypercalcemia), Any Grade Increase21
Calcium (hypercalcemia), Increase to G111
Calcium (hypercalcemia), Increase to G210
Calcium (hypercalcemia), Increase to G300
Calcium (hypercalcemia), Increase to G400
Glu. (hypoglycemia), Any Grade Increase3190
Glu. (hypoglycemia), Increase to G11745
Glu. (hypoglycemia), Increase to G21031
Glu. (hypoglycemia), Increase to G349
Glu. (hypoglycemia), Increase to G405
Glu. (hyperglycemia), Any Grade Increase128277
Glu. (hyperglycemia), Increase to G13168
Glu. (hyperglycemia), Increase to G277161
Glu. (hyperglycemia), Increase to G31944
Glu. (hyperglycemia), Increase to G414
Pot. (hyperkalemia), Any Grade Increase315
Pot. (hyperkalemia), Increase to G127
Pot. (hyperkalemia), Increase to G213
Pot. (hyperkalemia), Increase to G302
Pot. (hyperkalemia), Increase to G403
Pot. (hypokalemia), Any Grade Increase5374
Pot. (hypokalemia), Increase to G14866
Pot. (hypokalemia), Increase to G256
Pot. (hypokalemia), Increase to G302
Pot. (hypokalemia), Increase to G400
Sod. (hypernatremia), Any Grade Increase1421
Sod. (hypernatremia), Increase to G11420
Sod. (hypernatremia), Increase to G201
Sod. (hypernatremia), Increase to G300
Sod. (hypernatremia), Increase to G400
Sod. (hyponatremia), Any Grade Increase72128
Sod. (hyponatremia), Increase to G169118
Sod. (hyponatremia), Increase to G238
Sod. (hyponatremia), Increase to G301
Sod. (hyponatremia), Increase to G401
SecondaryNumber of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters (Hemoglobin, Lymphocytes [Lym.], Total Neutrophils [Tot Neu.], and White Blood Cells [WBC]), Per DAIDS

Blood samples for the assessment of hematology parameters were taken at intervals throughout the study. Participants with the worst-case shift from BL during the DB Phase are reported, per severity grades by DAIDS, for levels of hemoglobin (low=anemia), lymphocytes (low=lymphocytopenia), total neutrophils (low=neutropenia), and white blood cells (low=leukocytopenia). Per the DAIDS toxicity table, grade ranges for each parameter are as follows: Grade (G) 1=mild; G2=moderate; G3=severe; G4=potentially life-threatening.

Time frame:
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Reported as:
Number · participants
Number of Participants With the Indicated Shifts From BL in Severity Grades for for Hematology Parameters (Hemoglobin, Lymphocytes [Lym.], Total Neutrophils [Tot Neu.], and White Blood Cells [WBC]), Per DAIDS
participantsPlacebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB Phase
Hemoglobin (anemia), Any Grade Increase161361
Hemoglobin (anemia), Increase to G146112
Hemoglobin (anemia), Increase to G264129
Hemoglobin (anemia), Increase to G348114
Hemoglobin (anemia), Increase to G436
Lym. (lymphocytopenia), Any Grade Increase136346
Lym. (lymphocytopenia), Increase to G11643
Lym. (lymphocytopenia), Increase to G23880
Lym. (lymphocytopenia), Increase to G348109
Lym. (lymphocytopenia), Increase to G434114
Tot Neu. (neutropenia), Any Grade Increase208394
Tot Neu. (neutropenia), Increase to G150106
Tot Neu. (neutropenia), Increase to G253113
Tot Neu. (neutropenia), Increase to G373128
Tot Neu. (neutropenia), Increase to G43247
WBC (leukocytopenia), Any Grade Increase191391
WBC (leukocytopenia), Increase to G156113
WBC (leukocytopenia), Increase to G269145
WBC (leukocytopenia), Increase to G358110
WBC (leukocytopenia), Increase to G4823
SecondaryNumber of Participants in the Indicated Categories for Cataract Event During the DB Phase, Per Clinical Events Committee (CEC) Adjudication

Ophthalmic (pertaining to eye) assessments were performed during the study. A cataract event is defined as an event ascertained to be a cataract (opacity or cloudiness of the lens of the eye, causing impairment of vision) by at least one of the CEC members (comprised of expert ophthalmologists who provided objective medical review of the blinded ophthalmic data). Per the CEC, cataract events were categorized as: (1) Cataract Progression (CP; progression of cataracts present at BL); and (2) Incident Cataract (IC; development of new cataracts). One eye=unilateral; both eyes=bilateral.

Time frame:
From Baseline up to Week 48 or Week 72 (for participants with Genotype 2/3) or up to Week 72 (for participants with Non-Genotype 2/3)
Reported as:
Number · participants
Number of Participants in the Indicated Categories for Cataract Event During the DB Phase, Per Clinical Events Committee (CEC) Adjudication
participantsPlacebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB Phase
Unilateral CP, Genotype 2/301
Unilateral CP, Non-genotype 2/346
Bilateral CP, Genotype 2/331
Bilateral CP, Non-genotype 2/317
Unilateral IP, Genotype 2/314
Unilateral IP, Non-genotype 2/316
Bilateral IP, Genotype 2/331
Bilateral IP, Non-genotype 2/3310
SecondaryNumber of Participants Assessed as Normal and Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at the Indicated Time Points During the DB Phase

Duplicate 12-lead ECGs were required at Screening/BL, Antiviral BL, and at 12 weekly intervals during the study. The number of participants with an ECG status of normal, abnormal, CS, or NCS, as determined by the Investigator, was reported. Normal, all ECG parameters within accepted normal ranges. Abnormal, ECG finding(s) outside of normal ranges. CS, ECG with a CS abnormality that meets exclusion criteria. NCS, ECG with an abnormality not CS or meeting exclusion criteria, per Investigator, based on reasonable standards of clinical judgment.

Time frame:
DB Phase: Antiviral BL (up to Week 10); End of Treatment (up to Week 52); and 24-week FU (up to Week 72)
Reported as:
Number · participants
Number of Participants Assessed as Normal and Abnormal (Clinically Significant [CS] and Not Clinically Significant [NCS]) for 12-lead Electrocardiogram (ECG) at the Indicated Time Points During the DB Phase
participantsPlacebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB Phase
Antiviral BL, Normal, n=232, 478147332
Antiviral BL, Abnormal - NCS, n=232, 47863103
Antiviral BL, Abnormal - CS, n=232, 4782243
End of Treatment, Normal, n=218, 428134291
End of Treatment, Abnormal - NCS, n=218, 42862103
End of Treatment, Abnormal - CS, n=218, 4282234
24-week FU, Normal, n=194, 383123238
24-week FU, Abnormal - NCS, n=194, 38349107
24-week FU, Abnormal - CS, n=194, 3832238
Worst ECG post-BL, Normal, n=252, 505113233
Worst ECG post-BL, Abnormal - NCS, n=252, 50591171
Worst ECG post-BL, Abnormal - CS, n=252, 50548101
SecondaryNumber of Participants With CS and NCS Change From Baseline for 12-lead ECG at the Indicated Time Points During the DB Phase

Duplicate 12-lead ECGs were required at Screening/BL, Antiviral BL, and at 12 weekly intervals during the study. The number of participants with a CS and a NCS change from baseline in ECG status, as determined by the Investigator, was reported. CS, ECG with a CS abnormality that meets exclusion criteria. NCS, ECG with an abnormality not CS or meeting exclusion criteria, per Investigator, based on reasonable standards of clinical judgment. "Not applicable" indicates that information was not provided by the investigator on whether the change from baseline ECG was CS or NCS.

Time frame:
End of Treatment (up to Week 52); and 24-week FU (up to Week 72)
Reported as:
Number · participants
Number of Participants With CS and NCS Change From Baseline for 12-lead ECG at the Indicated Time Points During the DB Phase
participantsPlacebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB Phase
End of Treatment, CS change from BL, n=218, 42807
End of Treatment, NCS change from BL, n=218, 428218420
End of Treatment, Not applicable, n=218, 42801
24-week FU, CS change from BL, n=194, 38314
24-week FU, NCS change from BL, n=194, 383193379
SecondaryMean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points During the DB Phase

Participant's blood pressure was measured at the indicated time points during the study. Systolic blood pressure is a measure of blood pressure while the heart is beating. Diastolic blood pressure is a measure of blood pressure while the heart is relaxed. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.

Time frame:
DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)
Reported as:
Mean · Millimeters of mercury (mmHg)
Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points During the DB Phase
Millimeters of mercury (mmHg)Placebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB Phase
SBP, Week 1, n=246, 491-3.00 ± 13.541-2.36 ± 12.296
SBP, Week 2, n=242, 494-3.25 ± 13.800-3.74 ± 13.122
SBP, Week 4, n=228, 485-3.75 ± 13.781-3.91 ± 13.780
SBP, Week 6, n=206, 471-3.36 ± 14.405-3.85 ± 14.624
SBP, Week 8, n=190, 472-2.72 ± 14.073-4.33 ± 14.401
SBP, Week 12, n=175, 452-2.16 ± 15.297-4.30 ± 14.377
SBP, Week 16, n=143, 403-3.16 ± 15.426-4.59 ± 13.579
SBP, Week 20, n=133, 374-2.50 ± 14.387-4.12 ± 14.908
SBP, Week 24, n=99, 263-1.97 ± 14.820-3.94 ± 14.917
SBP, Week 28, n=74, 211-0.69 ± 14.663-4.99 ± 14.557
SBP, Week 32, n=67, 197-1.46 ± 13.904-5.61 ± 13.523
SBP, Week 36, n=62, 186-1.31 ± 13.803-4.40 ± 14.842
SBP, Week 40, n=59, 1730.10 ± 13.605-4.31 ± 13.941
SBP, Week 44, n=59, 1670.56 ± 11.689-4.54 ± 13.794
SBP, End of Treatment, n=238, 468-2.03 ± 13.259-3.98 ± 15.318
SBP, 4-week FU, n=221, 426-1.14 ± 14.095-1.65 ± 15.122
SBP, 12-week FU, n=207, 432-0.11 ± 14.113-0.86 ± 14.806
SBP, 24-week FU, n=203, 3981.10 ± 14.5450.25 ± 14.518
DBP, Week 1, n=246, 491-1.43 ± 9.235-1.37 ± 8.224
DBP, Week 2, n=242, 493-1.55 ± 9.217-1.86 ± 8.946
DBP, Week 4, n=228, 485-1.84 ± 9.726-2.72 ± 9.467
DBP, Week 6, n=206, 471-2.16 ± 8.939-2.95 ± 9.859
DBP, Week 8, n=190, 472-1.24 ± 9.517-2.68 ± 9.901
DBP, Week 12, n=175, 452-1.31 ± 8.781-3.23 ± 10.025
DBP, Week 16, n=143, 403-1.54 ± 9.684-3.31 ± 9.899
DBP, Week 20, n=133, 374-0.93 ± 10.582-3.08 ± 9.606
DBP, Week 24, n=99, 263-1.66 ± 10.207-3.54 ± 9.313
DBP, Week 28, n=74, 211-1.23 ± 9.538-3.42 ± 10.502
DBP, Week 32, n=67, 197-0.54 ± 10.445-3.76 ± 9.527
DBP, Week 36, n=62, 186-0.74 ± 9.559-3.59 ± 9.211
DBP, Week 40, n=59, 1730.34 ± 9.343-3.32 ± 9.517
DBP, Week 44, n=59, 1670.92 ± 9.033-3.77 ± 10.134
DBP, End of Treatment, n=238, 468-1.55 ± 9.174-3.59 ± 10.254
DBP, 4-week FU, n=221, 426-0.83 ± 9.102-2.20 ± 9.824
DBP, 12-week FU, n=207, 432-0.78 ± 10.253-1.76 ± 9.903
DBP, 24-week FU, n=203, 3980.03 ± 9.814-1.61 ± 9.339
SecondaryMean Change From Baseline in Heart Rate at the Indicated Time Points During the DB Phase

Heart rate was measured in participants at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.

Time frame:
DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)
Reported as:
Mean · beats per minute
Mean Change From Baseline in Heart Rate at the Indicated Time Points During the DB Phase
beats per minutePlacebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB Phase
Week 1, n=244, 4901.16 ± 8.358-0.43 ± 8.629
Week 2, n=242, 4901.89 ± 8.5100.78 ± 9.644
Week 4, n=227, 4832.47 ± 9.4641.50 ± 9.739
Week 6, n=205, 4703.23 ± 9.1581.19 ± 8.708
Week 8, n=190, 4722.91 ± 9.7511.78 ± 9.227
Week 12, n=174, 4504.28 ± 10.1882.02 ± 9.539
Week 16, n=143, 4035.87 ± 9.9752.38 ± 10.419
Week 20, n=132, 3715.73 ± 9.6882.10 ± 9.530
Week 24, n=99, 2623.77 ± 9.9122.03 ± 9.399
Week 28, n=74, 2112.72 ± 10.0381.64 ± 10.328
Week 32, n=67, 1964.28 ± 8.2811.62 ± 9.676
Week 36, n=62, 1865.42 ± 10.1092.11 ± 10.205
Week 40, n=59, 1714.83 ± 8.9190.78 ± 9.895
Week 44, n=59, 1655.53 ± 11.0051.16 ± 8.846
End of Treatment, n=237, 4674.01 ± 10.6062.89 ± 11.134
4-week FU, n=220, 4224.27 ± 10.4322.11 ± 10.113
12-week FU, n=206, 4291.73 ± 9.7070.74 ± 9.955
24-week FU, n=202, 3950.14 ± 9.803-1.90 ± 9.176
SecondaryMean Change From Baseline in Weight at the Indicated Time Points During the DB Phase

The weight of participants was recorded at the indicated time points. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.

Time frame:
DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)
Reported as:
Mean · Kilograms (kg)
Mean Change From Baseline in Weight at the Indicated Time Points During the DB Phase
Kilograms (kg)Placebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB Phase
Week 1, n=248, 492-0.65 ± 2.201-0.68 ± 2.062
Week 2, n=244, 495-0.88 ± 1.983-1.06 ± 2.809
Week 4, n=229, 488-1.30 ± 2.374-1.30 ± 2.488
Week 6, n=207, 476-1.42 ± 2.464-1.68 ± 2.652
Week 8, n=191, 473-1.89 ± 2.793-2.11 ± 2.810
Week 12, n=175, 453-2.18 ± 2.985-2.83 ± 3.440
Week 16, n=145, 406-2.37 ± 3.247-3.32 ± 3.798
Week 20, n=134, 378-3.08 ± 3.684-3.99 ± 4.040
Week 24, n=99, 265-4.04 ± 4.148-4.75 ± 4.175
Week 28, n=74, 212-4.57 ± 4.749-5.09 ± 5.016
Week 32, n=67, 200-4.50 ± 4.397-5.52 ± 5.369
Week 36, n=63, 188-4.54 ± 4.739-5.39 ± 7.476
Week 40, n=59, 174-4.99 ± 4.612-5.87 ± 5.571
Week 44, n=59, 168-4.79 ± 5.475-5.89 ± 5.661
End of Treatment, n=240, 470-3.28 ± 4.361-4.69 ± 5.180
4-week FU, n=223, 425-2.78 ± 4.318-3.84 ± 6.381
12-week FU, n=210, 434-1.98 ± 4.088-2.99 ± 5.999
24-week FU, n=205, 401-1.36 ± 4.568-1.51 ± 7.683
SecondaryMean Change From Baseline in Body Mass Index (BMI) at the Indicated Time Points During the DB Phase

The BMI for participants was calculated at the indicated time points as body weight in kilograms divided by height in meters squared. Mean change from Baseline was calculated as the value at the indicated time points minus the value at Baseline.

Time frame:
DB Phase: Baseline; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44; End of Treatment (up to Week 48); 4-week Follow-up (FU) (up to Week 52); 12-week FU (up to Week 60); and 24-week FU (up to Week 72)
Reported as:
Mean · Kilograms per meters squared (kg/m^2)
Mean Change From Baseline in Body Mass Index (BMI) at the Indicated Time Points During the DB Phase
Kilograms per meters squared (kg/m^2)Placebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB Phase
Week 1, n=248, 490-0.23 ± 0.771-0.23 ± 0.713
Week 2, n=244, 493-0.31 ± 0.691-0.36 ± 0.921
Week 4, n=229, 486-0.46 ± 0.823-0.45 ± 0.855
Week 6, n=207, 474-0.50 ± 0.871-0.58 ± 0.893
Week 8, n=191, 471-0.66 ± 0.967-0.73 ± 0.955
Week 12, n=175, 451-0.77 ± 1.055-0.97 ± 1.167
Week 16, n=145, 404-0.85 ± 1.158-1.15 ± 1.285
Week 20, n=134, 376-1.11 ± 1.324-1.39 ± 1.377
Week 24, n=99, 264-1.46 ± 1.509-1.66 ± 1.624
Week 28, n=74, 211-1.67 ± 1.731-1.79 ± 1.733
Week 32, n=67, 199-1.64 ± 1.586-1.94 ± 1.844
Week 36, n=63, 187-1.65 ± 1.703-1.89 ± 2.651
Week 40, n=59, 173-1.81 ± 1.671-2.09 ± 1.953
Week 44, n=59, 167-1.73 ± 2.007-2.09 ± 1.942
End of Treatment, n=240, 468-1.16 ± 1.553-1.64 ± 1.783
4-week FU, n=223, 423-0.98 ± 1.519-1.35 ± 2.306
12-week FU, n=210, 432-0.70 ± 1.434-1.06 ± 2.055
24-week FU, n=205, 399-0.47 ± 1.544-0.53 ± 2.736

Adverse events

Collected over Adverse events (AEs) are reported for the Double-blind (DB) on-treatment + 30 days period (up to Study Week 52).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eltrombopag: OL Phase—9/805 (1.1%)0/805 (0%)
Placebo+Antiviral Therapy: DB Phase—49/252 (19.4%)226/252 (89.7%)
Eltrombopag+Antiviral Therapy: DB Phase—119/506 (23.5%)459/506 (90.7%)
Most frequent serious events
Showing 10 of 162
Most frequent serious events
EventEltrombopag: OL PhasePlacebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB Phase
Hepatic neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/8057/25222/506
Hepatic encephalopathyNervous system disorders0/8051/2529/506
CataractEye disorders0/8051/2529/506
PneumoniaInfections and infestations1/8054/2527/506
Esophageal varices hemorrhageGastrointestinal disorders0/8054/2524/506
AscitesGastrointestinal disorders0/8052/2526/506
Gastrointestinal hemorrhageGastrointestinal disorders0/8050/2525/506
AnemiaBlood and lymphatic system disorders0/8052/2525/506
ThrombocytopeniaBlood and lymphatic system disorders0/8051/2525/506
Urinary tract infectionInfections and infestations1/8052/2521/506
Most frequent other events
Showing 10 of 39
Most frequent other events
EventEltrombopag: OL PhasePlacebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB Phase
AnemiaBlood and lymphatic system disorders0/80590/252200/506
NeutropeniaBlood and lymphatic system disorders0/80583/252139/506
ThrombocytopeniaBlood and lymphatic system disorders0/80583/25261/506
PyrexiaGeneral disorders0/80560/252141/506
FatigueGeneral disorders0/80553/252124/506
HeadacheNervous system disorders0/80550/25295/506
Influenza like illnessGeneral disorders0/80536/252100/506
Decreased appetiteMetabolism and nutrition disorders0/80536/25294/506
NauseaGastrointestinal disorders0/80538/25292/506
DiarrheaGastrointestinal disorders0/80524/25292/506

Baseline characteristics

Age Continuous
Age Continuous(Years)Placebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB PhaseTotal
Mean52.0 ± 9.1552.4 ± 8.6152.3 ± 8.79
Sex: Female, Male
Sex: Female, Male(Participants)Placebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB PhaseTotal
Female93185278
Male160321481
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Placebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB PhaseTotal
African American (A)/African4812
American Indian or Alaska Native011
White (W)188388576
Central/South Asian164359
Japanese/East Asian /South East Asian4564109
American Indian or Alaska Native and White011
African A/African and A Indian/Alaska Native and W011
Number of participants categorized into the indicated genotype for Hepatitic C Virus (HCV)
Number of participants categorized into the indicated genotype for Hepatitic C Virus (HCV)(participants)Placebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB PhaseTotal
Genotype 1160320480
Genotype 2284068
Genotype 347113160
Genotype 4173047
Genotype 5000
Genotype 6011
Genotype 7000
Missing123
Number of participants categorized into the indicated Child-Pugh (CP) Class
Number of participants categorized into the indicated Child-Pugh (CP) Class(participants)Placebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB PhaseTotal
Class A242487729
Class B111728
Class C000
Missing022
Number of participants with or without previous interferon (IFN) use
Number of participants with or without previous interferon (IFN) use(participants)Placebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB PhaseTotal
Naïve182347529
Experienced71159230
Number of participants with the indicated FibroTest/Acti Test (FibroSURE) score
Number of participants with the indicated FibroTest/Acti Test (FibroSURE) score(participants)Placebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB PhaseTotal
Score: F0/F1/F2194665
Score: F3/F4199405604
Missing355590
Number of participants with normal or elevated Baseline values for Alanine Aminotransferase (ALT)
Number of participants with normal or elevated Baseline values for Alanine Aminotransferase (ALT)(participants)Placebo+Antiviral Therapy: DB PhaseEltrombopag+Antiviral Therapy: DB PhaseTotal
Normal49113162
Elevated204393597

2 further baseline measures are reported on the registry.

08

Study locations

227 sites
  • GSK Investigational Site
    Birmingham, Alabama 35294-0005, United States
  • GSK Investigational Site
    Tucson, Arizona 85750, United States
  • GSK Investigational Site
    Anaheim, California 92801, United States
  • GSK Investigational Site
    Arcadia, California 91007, United States
  • GSK Investigational Site
    La Jolla, California 92037, United States
  • GSK Investigational Site
    Los Angeles, California 90017, United States
  • GSK Investigational Site
    Los Angeles, California 90048, United States
  • GSK Investigational Site
    Lynwood, California 90262, United States
  • GSK Investigational Site
    Sacramento, California 95817, United States
  • GSK Investigational Site
    San Clemente, California 92673, United States
  • GSK Investigational Site
    San Diego, California 92123, United States
  • GSK Investigational Site
    San Mateo, California 94403, United States
  • GSK Investigational Site
    Aurora, Colorado 80045, United States
  • GSK Investigational Site
    New Haven, Connecticut 06510, United States
  • GSK Investigational Site
    Washington, District of Columbia 20010, United States
  • GSK Investigational Site
    Washington, District of Columbia 20307, United States
  • GSK Investigational Site
    Bradenton, Florida 34209, United States
  • GSK Investigational Site
    Jacksonville, Florida 32207, United States
  • GSK Investigational Site
    Miami, Florida 33125, United States
  • GSK Investigational Site
    Honolulu, Hawaii 96817, United States
  • GSK Investigational Site
    Chicago, Illinois 60612-3824, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
  • GSK Investigational Site
    Lexington, Kentucky 40536, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70112, United States
  • GSK Investigational Site
    Boston, Massachusetts 02215, United States
  • GSK Investigational Site
    Burlington, Massachusetts 01805, United States
  • GSK Investigational Site
    Worcester, Massachusetts 01655, United States
  • GSK Investigational Site
    Detroit, Michigan 48201, United States
  • GSK Investigational Site
    Detroit, Michigan 48202, United States
  • GSK Investigational Site
    Jackson, Mississippi 39202, United States
  • GSK Investigational Site
    St. Louis, Missouri 63104, United States
  • GSK Investigational Site
    St. Louis, Missouri 63110, United States
  • GSK Investigational Site
    Lebanon, New Hampshire 03756, United States
  • GSK Investigational Site
    Bronx, New York 10468, United States
  • GSK Investigational Site
    Manhasset, New York 11030, United States
  • GSK Investigational Site
    New York, New York 10016, United States
  • GSK Investigational Site
    New York, New York 10021, United States
  • GSK Investigational Site
    Rochester, New York 14642, United States
  • GSK Investigational Site
    Syracuse, New York 13210, United States
  • GSK Investigational Site
    Asheville, North Carolina 28801, United States
  • GSK Investigational Site
    Durham, North Carolina 27710, United States
  • GSK Investigational Site
    Kinston, North Carolina 28501, United States
  • GSK Investigational Site
    Morganton, North Carolina 28655, United States
  • GSK Investigational Site
    Tulsa, Oklahoma 74104, United States
  • GSK Investigational Site
    Portland, Oregon 97239, United States
  • GSK Investigational Site
    Hershey, Pennsylvania 17033-0850, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • GSK Investigational Site
    Germantown, Tennessee 38138, United States
  • GSK Investigational Site
    Mountain Home, Tennessee 37684, United States
  • GSK Investigational Site
    Nashville, Tennessee 37203, United States
  • GSK Investigational Site
    Nashville, Tennessee 37205, United States
  • GSK Investigational Site
    Nashville, Tennessee 37212, United States
  • GSK Investigational Site
    Dallas, Texas 75203, United States
  • GSK Investigational Site
    Galveston, Texas 77555-0435, United States
  • GSK Investigational Site
    Houston, Texas 77030, United States
  • GSK Investigational Site
    San Antonio, Texas 78215, United States
  • GSK Investigational Site
    Charlottesville, Virginia 22908, United States
  • GSK Investigational Site
    Richmond, Virginia 23249, United States
  • GSK Investigational Site
    Seattle, Washington 98111, United States
  • GSK Investigational Site
    Garran, Australian Capital Territory 2606, Australia
  • GSK Investigational Site
    Camperdown, New South Wales 2050, Australia
  • GSK Investigational Site
    Randwick, New South Wales 2031, Australia
  • GSK Investigational Site
    Cairns, Queensland 4870, Australia
  • GSK Investigational Site
    Herston, Queensland 4029, Australia
  • GSK Investigational Site
    Clayton, Victoria 3168, Australia
  • GSK Investigational Site
    Fitzroy, Victoria 3065, Australia
  • GSK Investigational Site
    Parkville, Victoria 3050, Australia
  • GSK Investigational Site
    Prahran, Victoria 3181, Australia
  • GSK Investigational Site
    Nedlands, Western Australia 6009, Australia
  • GSK Investigational Site
    Bruxelles, 1200, Belgium
  • GSK Investigational Site
    Edegem, 2650, Belgium
  • GSK Investigational Site
    Gent, 9000, Belgium
  • GSK Investigational Site
    Leuven, 3000, Belgium
  • GSK Investigational Site
    Campinas, São Paulo 13083-888, Brazil
  • GSK Investigational Site
    São Paulo, 04023900, Brazil
  • GSK Investigational Site
    Edmonton, Alberta T6G 2C8, Canada
  • GSK Investigational Site
    Victoria, British Columbia V8V 3P9, Canada
  • GSK Investigational Site
    Winnipeg, Manitoba R3E 3P4, Canada
  • GSK Investigational Site
    Barrie, Ontario L4M 7G1, Canada
  • GSK Investigational Site
    Hamilton, Ontario L8L 2X2, Canada
  • GSK Investigational Site
    Hamilton, Ontario L8N 4A6, Canada
  • GSK Investigational Site
    London, Ontario N6A 5A5, Canada
  • GSK Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 1X5, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2C4, Canada
  • GSK Investigational Site
    Toronto, Ontario M5T 2S8, Canada
  • GSK Investigational Site
    Toronto, Ontario M6H 3M1, Canada
  • GSK Investigational Site
    Montreal, Quebec H2X 3J4, Canada
  • GSK Investigational Site
    Montreal, Quebec H3T 1E2, Canada
  • GSK Investigational Site
    Hradec Kralove, 500 12, Czech Republic
  • GSK Investigational Site
    Olomouc, 775 20, Czech Republic
  • GSK Investigational Site
    Praha 6, 169 02, Czech Republic
  • GSK Investigational Site
    Cairo, Egypt
  • GSK Investigational Site
    Mansoura, 35516, Egypt
  • GSK Investigational Site
    Shebeen El-Kom, Menoufeya, 35111, Egypt
  • GSK Investigational Site
    Besançon, 25030, France
  • GSK Investigational Site
    Bondy, 93140, France
  • GSK Investigational Site
    Dijon cedex, 21019, France
  • GSK Investigational Site
    Grenoble, 38043, France
  • GSK Investigational Site
    Lille, 59037, France

Showing the first 100 of 227 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Saleh MI, Obeidat AR, Anter HA, Khanfar AA. Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection. Clin Exp Pharmacol Physiol. 2015 Oct;42(10):1030-5. doi: 10.1111/1440-1681.12451. PubMed 26173631 ↗
  • Giannini EG, Afdhal NH, Sigal SH, Muir AJ, Reddy KR, Vijayaraghavan S, Elkashab M, Romero-Gomez M, Dusheiko GM, Iyengar M, Vasey SY, Campbell FM, Theodore D. Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy. J Gastroenterol Hepatol. 2015 Aug;30(8):1301-8. doi: 10.1111/jgh.12942. PubMed 25777337 ↗
  • Afdhal NH, Dusheiko GM, Giannini EG, Chen PJ, Han KH, Mohsin A, Rodriguez-Torres M, Rugina S, Bakulin I, Lawitz E, Shiffman ML, Tayyab GU, Poordad F, Kamel YM, Brainsky A, Geib J, Vasey SY, Patwardhan R, Campbell FM, Theodore D. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. Gastroenterology. 2014 Feb;146(2):442-52.e1. doi: 10.1053/j.gastro.2013.10.012. Epub 2013 Oct 12. PubMed 24126097 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in May 2012, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2007
First posted
Sep 14, 2007
Start
Oct 2007
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Results first posted
May 17, 2012
Last update
Nov 5, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00529568
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 14, 2007
Start date
Oct 2007
Primary completion
Aug 2011
Completion
Aug 2011
Results posted
May 17, 2012
Last update
Nov 5, 2013

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion